Rotating Resonator-Oscillator Experiments to Test Lorentz Invariance in Electrodynamics

In this work we outline the two most commonly used test theories (RMS and SME) for testing Local Lorentz Invariance (LLI) of the photon. Then we develop the general framework of applying these test theories to resonator experiments with an emphasis on rotating experiments in the laboratory. We compare the inherent sensitivity factors of common experiments and propose some new configurations. Finally we apply the test theories to the rotating cryogenic experiment at the University of Western Australia, which recently set new limits in both the RMS and SME frameworks [hep-ph/0506074].Comment: Submitted to Lecture Notes in Physics, 36 pages, minor modifications, updated list of reference

Testing General Relativity with Atomic Clocks

We discuss perspectives for new tests of general relativity which are based on recent technological developments as well as new ideas. We focus our attention on tests performed with atomic clocks and do not repeat arguments present in the other contributions to the present volume. In particular, we present the scientific motivations of the space projects ACES and SAGAS.Comment: Contribution for "The Nature of Gravity" (eds. F. Everitt et al

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

Background: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagonlike peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. Methods: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallelgroup, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. Results: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m2, and duration of T2DM was 9.3±8.2 years. The qualifying ACS wasamyocardial infarctionin83% and unstableangina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. Conclusion: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk. © 2015 Elsevier Inc. All rights reserved